Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Nye behandlingsmuligheder ved primær immun trombocytopeni

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Gudbrandsdottir, Sif ; Frederiksen, Henrik ; Birgens, Henrik Sverre ; Nielsen, Claus Henrik ; Nielsen, Ove Juul ; Stentoft, Jesper ; Hasselbalch, Hans Carl. / Nye behandlingsmuligheder ved primær immun trombocytopeni. In: Ugeskrift for Laeger. 2011 ; Vol. 173, No. 4. pp. 271-4.

Bibtex

@article{becca45452bb4968be86a2f19bdf3b71,
title = "Nye behandlingsmuligheder ved prim{\ae}r immun trombocytopeni",
abstract = "Primary immune thrombocytopenia (ITP)--formerly known as idiopathic thrombocytopenic purpura--is an autoimmune disorder characterized by immune mediated thrombocytopenia. The aetiology of ITP remains unknown, but studies have shown that multiple immunological mechanisms are involved in the pathogenesis of ITP. This article aims to provide an overview of current treatment options, with particular emphasis on new biological therapies: rituximab, a monoclonal anti-CD20 antibody, and the thrombopoietin receptor agonists romiplostim and eltrombopag.",
author = "Sif Gudbrandsdottir and Henrik Frederiksen and Birgens, {Henrik Sverre} and Nielsen, {Claus Henrik} and Nielsen, {Ove Juul} and Jesper Stentoft and Hasselbalch, {Hans Carl}",
year = "2011",
month = "1",
day = "24",
language = "Dansk",
volume = "173",
pages = "271--4",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "4",

}

RIS

TY - JOUR

T1 - Nye behandlingsmuligheder ved primær immun trombocytopeni

AU - Gudbrandsdottir, Sif

AU - Frederiksen, Henrik

AU - Birgens, Henrik Sverre

AU - Nielsen, Claus Henrik

AU - Nielsen, Ove Juul

AU - Stentoft, Jesper

AU - Hasselbalch, Hans Carl

PY - 2011/1/24

Y1 - 2011/1/24

N2 - Primary immune thrombocytopenia (ITP)--formerly known as idiopathic thrombocytopenic purpura--is an autoimmune disorder characterized by immune mediated thrombocytopenia. The aetiology of ITP remains unknown, but studies have shown that multiple immunological mechanisms are involved in the pathogenesis of ITP. This article aims to provide an overview of current treatment options, with particular emphasis on new biological therapies: rituximab, a monoclonal anti-CD20 antibody, and the thrombopoietin receptor agonists romiplostim and eltrombopag.

AB - Primary immune thrombocytopenia (ITP)--formerly known as idiopathic thrombocytopenic purpura--is an autoimmune disorder characterized by immune mediated thrombocytopenia. The aetiology of ITP remains unknown, but studies have shown that multiple immunological mechanisms are involved in the pathogenesis of ITP. This article aims to provide an overview of current treatment options, with particular emphasis on new biological therapies: rituximab, a monoclonal anti-CD20 antibody, and the thrombopoietin receptor agonists romiplostim and eltrombopag.

M3 - Tidsskriftartikel

VL - 173

SP - 271

EP - 274

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 4

ER -

ID: 31047030